Skip to content
PeptideTech
Cart

Home / Research library / Tesamorelin

Peptides

Tesamorelin: molecular data, studies & sources

Tesamorelin is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular formula (MF)
C221H366N72O67S
Molecular weight (MW)
5136 g/mol
PubChem compound ID
16137828
Record title
Tesamorelin

Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.

Source: PubChem CID 16137828 · retrieved 2026-09-21

2D molecular structure for Tesamorelin, PubChem CID 16137828
2D depiction from PubChem. Open to inspect the full image. This drawing represents the selected record, not a vendor batch test.
Chemical identifiers and source data
IUPAC name
(4S)-4-[[2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-3-carboxy-2-[[(2S)-2-[[(2S)-2-[[(E)-hex-3-enoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-3-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-5-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
InChIKey
QBEPNUQJQWDYKU-BMGKTWPMSA-N
SMILES
CC/C=C/CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N
Machine-readable PubChem source
Calculated molecular descriptors
Monoisotopic (exact) mass5132.7166 Da
Heavy atoms361
Hydrogen-bond donors83
Hydrogen-bond acceptors72
Rotatable bonds181
Topological polar surface area2339.4 Ų
Calculated logP (Crippen)-27.03
Rings3
Stereocenters44
Formal charge0

Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.

Registered clinical trials

Studies registered on ClinicalTrials.gov that list Tesamorelin as an intervention. Studies that only measure the molecule as a biomarker are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

17 registered studies matched, 3 currently active or recruiting.

StudyPhase · statusConditionsSponsor · size
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Tesamorelin (GHRH Analog) for Reducing Hepatic Steatosis in Adults With Metabolic Associated Steatotic Liver Disease (MASLD)NCT07481734 · start 2026-02-02 · primary completion 2027-02-14Phase 2RecruitingMetabolic Associated Steatotic Liver Disease · Nonalcoholic Steatohepatitis · Hepatic SteatosisHudson Biotech120 participants
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIVNCT06554717 · start 2025-07-10 · primary completion 2028-06-16Phase 2RecruitingHIV-1-infection · Frailty · Impaired Physical Function · Abdominal Obesity · AgingMassachusetts General Hospital100 participants
Tesamorelin Therapy to Enhance Axonal Regeneration, Minimize Muscle Atrophy, and Improve Functional Outcomes Following Peripheral Nerve InjuryNCT03150511 · start 2018-06-01 · primary completion 2027-12Phase 2RecruitingPeripheral Nerve InjuriesJohns Hopkins University36 participants
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular RiskNCT03375788 · start 2019-01-17 · primary completion 2024-07-10Phase 2CompletedNon-Alcoholic Fatty Liver Disease · Obesity · Obesity, Abdominal · Liver Fat · Fatty LiverMassachusetts General Hospital51 participants
Body Composition and Adipose Tissue in HIV Lipodystrophy: Effects of Tesamorelin TherapyNCT03226821 · start 2018-02-07 · primary completion 2025-04-30Phase 4TerminatedHIV Lipodystrophy Syndrome · Growth Hormone Deficiency · Body CompositionColumbia University6 participants
Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected PersonsNCT02572323 · start 2017-02-15 · primary completion 2023-10-15Phase 2CompletedMild Cognitive ImpairmentUniversity of California, San Diego73 participants
The Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current InsomniaNCT02931474 · start 2016-10-06 · primary completion 2017-03-08Phase 2WithdrawnSleep Disorder · Traumatic Brain InjuryNational Institute of Nursing Research (NINR)Enrollment not listed
Tesamorelin Effects on Liver Fat and Histology in HIV: A Collaborative UO1 GrantNCT02196831 · start 2015-07-01 · primary completion 2019-01-16Not applicableCompletedHuman Immunodeficiency Virus (HIV) · Nonalcoholic Fatty Liver Disease (NAFLD) · Nonalcoholic Steatohepatitis (NASH)Massachusetts General Hospital61 participants
Abdominal Obesity, Cardiovascular Inflammation, and Effects of a Growth Hormone Releasing Hormone Analogue to Reduce InflammationNCT01632592 · start 2014-01 · primary completion 2014-01Not applicableWithdrawnAbdominal ObesityMassachusetts General HospitalEnrollment not listed
A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA®NCT01579695 · start 2013-02 · primary completion 2018-05Not applicableTerminatedHIVTheratechnologies391 participants
Show 7 more registered studies
StudyPhase · statusConditionsSponsor · size
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant DiabetesNCT01591902 · start 2012-06 · primary completion 2018-05Phase 4TerminatedDiabetic Retinopathy · HIVTheratechnologies129 participants
Egrifta Replacement and Sleep Disordered BreathingNCT01788462 · start 2012-05 · primary completion 2020-01Not applicableWithdrawnLipodystrophyJohns Hopkins UniversityEnrollment not listed
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Two Doses of Tesamorelin in Stable Ambulatory COPD Subjects With Muscle WastingNCT01388920 · start 2011-09 · primary completion 2011-12Phase 2TerminatedChronic Obstructive Pulmonary Disease (COPD)Theratechnologies3 participants
Effects of Growth Hormone Releasing Hormone on Fat Redistribution, Cardiovascular Indices, and Growth Hormone Secretion in HIV LipodystrophyNCT01263717 · start 2010-12 · primary completion 2014-02Not applicableCompletedHIV · HIV LipodystrophyMassachusetts General Hospital54 participants
Effect of Short Term Growth Hormone Releasing Hormone in Healthy MenNCT00850564 · start 2009-02 · primary completion 2010-04Not applicableCompletedHealthy VolunteersMassachusetts General Hospital15 participants
A Phase 1 Study to Evaluate the Pharmacokinetics and the Pharmacodynamics of TH9507 Administered Subcutaneously Once Daily for 14 Consecutive Days in HIV Positive PatientsNCT02012556 · start 2008-05 · primary completion 2008-07Phase 1CompletedHIVTheratechnologies18 participants
A Multicenter, Double-blind, Randomized, Placebo-controlled Extension Study Assessing the Efficacy and Long-term Safety of a 2 mg Dose of TH9507, a GHRH Analog, in HIV Subjects With Excess Abdominal Fat AccumulationNCT00608023 · start 2007-08 · primary completion 2008-10Phase 3CompletedLipodystrophy · HIV InfectionsTheratechnologies263 participants

Registry check 2026-10-01 · Run this search on ClinicalTrials.gov

Human and clinical studies

Selected human-study records are shown with their indexed or reviewed study type. Check the original article for the intervention, formulation and controls; the molecule can also be a comparator or measured variable.

  1. Human study · PubMed trial index

    Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.

    Russo SC, Ockene MW, Arpante AK et al. · AIDS (London, England) · 2024

    PMID 38905488 · DOI: 10.1097/QAD.0000000000003965

  2. Human study · PubMed trial index

    Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.

    Clemmons DR, Miller S, Mamputu JC et al. · PloS one · 2017

    PMID 28617838 · DOI: 10.1371/journal.pone.0179538

  3. Human study · PubMed trial index

    Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.

    Ellis RJ, Vaida F, Hu K et al. · The Journal of infectious diseases · 2025

    PMID 39813152 · DOI: 10.1093/infdis/jiaf012

  4. Human study · PubMed trial index

    Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.

    Stanley TL, Falutz J, Mamputu JC et al. · AIDS (London, England) · 2011

    PMID 21516030 · DOI: 10.1097/QAD.0b013e328347f3f1

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

No additional matching publication was retained. The search links below allow further investigation; they are not evidence that a study exists.

    Tesamorelin supplier sources

    Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

    Tesamorelin for sale: compare prices, sizes and forms from every tracked supplier →

    SupplierRecorded packagesExample source listing
    American PeptidesUSD10mg Vial · 20mg Vial2 recorded offers10mg Vial · $120.00Checked Oct 7, 2026Supplier listing
    Blank PeptidesUSD10mg Vial1 recorded offers10mg Vial · $75.00Stale observation · Checked Sep 30, 2026Supplier listing
    Amino ClubUSD10mg Vial1 recorded offers10mg Vial · $69.99Stale observation · Checked Sep 28, 2026Supplier listing
    Nova Peptide SupplyUSD5mg Vial · 10mg Vial · 20mg Vial3 recorded offers5mg Vial · $49.99Checked Oct 6, 2026Supplier listing
    Amino USAUSD10mg Vial · 2mg Vial · 5mg Vial3 recorded offers10mg Vial · $90.00Checked Oct 7, 2026Supplier listing
    Cenexa LabsUSD20mg Vial · 5mg Vial · 10mg Vial3 recorded offers20mg Vial · $129.99Checked Oct 7, 2026Supplier listing

    Reference sources & further reading

    The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

    Search for additional research

    These links run searches; their results have not been individually reviewed and can include unrelated compounds.

    Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.

    Related research profiles